Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis

Table 1 Clinical information of systemic sclerosis patients

No	Sex	Age range	Disease duration, years	Skin involvement	ILD	PAH	GI involvement	ANA	Anti-centromere	Anti-scl70
1	2	40–49	20	Limited	Yes, NSIP	No	GERD	1:80, nucleolar	Negative	Negative
2	1	40–49	13	Diffuse	Yes, NSIP + UIP	Yes	Recurrent paralytic ileus	1:1280, speckled	Negative	Negative
3	1	50–59	2	Diffuse	Yes, UIP	No	GERD	1:1280, cytoplasmic	Negative	Positive
4	2	60–69	5	Diffuse	Yes, NSIP	No	GERD	1:80, speckled	Negative	Negative
5	1	50–59	16	Diffuse	No	No	GERD, scleroderma esophagus	1:640, speckled	Negative	Negative

1, Female; 2, Male; ILD, interstitial lung disease; PAH, pulmonary artery hypertension; ANA, antinuclear antibody; NSIP, nonspecific interstitial pneumonia; UIP, usual interstitial pneumonia; GERD, gastroesophageal reflux disease

ISSN: 1757-6512